Pramlintide
Pramlintide is a peptide, indexed here under Amylin and amylin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Amylin and amylin receptor agonists |
| CAS registry number | 151126-32-8[1] |
| PubChem CID | 70691388[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C171H267N51O53S2[1] |
| Molecular weight | 3949 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Pramlintide is a synthetic analogue of amylin. The Drugs@FDA register returned an approved application under this generic name, recorded in the regulatory status field and not what this page describes. A 2001 Current Pharmaceutical Design paper frames it as amylin replacement as an adjunct to insulin in type 1 and type 2 diabetes, and 2002, 2003, 2004 and 2006 papers in Diabetes Care, Diabetic Medicine and Diabetes Technology and Therapeutics report long-term glycaemic and weight endpoints in insulin-treated patients.
Weight-specific records include a 2004 Obesity Research paper in overweight and obese insulin-treated patients, a 2005 Diabetologia paper on satiety and food intake, a 2007 Journal of Clinical Endocrinology and Metabolism phase 2 study in obese subjects, a 2008 Diabetes Care paper on twelve months of administration as an adjunct to lifestyle intervention, and a 2009 Obesity paper on combination with metreleptin.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A synthetic amylin analogue studied in the retrieved records as amylin replacement, with satiety and food intake endpoints.
[3, 10]Stated in the titles of the cited 2001 Current Pharmaceutical Design and 2005 Diabetologia papers.
Targets named in the cited records: amylin receptors.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA021332, marketed as SYMLIN). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Pramlintide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- Symlin
- pramlintide acetate
Where this page sits
Research records
Cited research records for Pramlintide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Amylin — Amylin and amylin receptor agonists
- Cagrilintide — Amylin and amylin receptor agonists
Class page: Amylin and amylin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Pramlintide?
Pramlintide is a synthetic analogue of amylin. The Drugs@FDA register returned an approved application under this generic name, recorded in the regulatory status field and not what this page describes.
Which class is Pramlintide indexed under?
Pramlintide is indexed under Amylin and amylin receptor agonists. This class groups the pancreatic hormone amylin, also called islet amyloid polypeptide, and the synthetic analogues modelled on it.
What does the FDA application register show for Pramlintide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA021332, marketed as SYMLIN). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 70691388, Pramlintide. PubChem, National Library of Medicine (2026). pubchem:70691388
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA021332. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:pramlintide
- Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
- A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes care (2002). pmid:11919132
- Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes care (2003). pmid:12610038
- Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association (2004). pmid:15498087
- A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes care (2006). pmid:17003291
- Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes technology & therapeutics (2002). pmid:12017421
- Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity research (2004). pmid:15090634
- Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia (2005). pmid:15843914
- Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of clinical endocrinology and metabolism (2007). pmid:17504894
- Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes care (2008). pmid:18753666
- Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md.) (2009). pmid:19521351
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.